Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 4Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Solid Tumor 1Sezary Syndrome 1Myeloid Malignancies 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × magrolimab × Clear all
NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Gilead Sciences

Phase 2 Terminated
36 enrolled 17 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡